Is Brukinsa (Zanubrutinib) a Safer Bruton’s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis

<b>Background/Objectives:</b> Zanubrutinib (Brukinsa) is a next-generation Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, a comprehensive quantitative assessment of its sa...

Descripció completa

Dades bibliogràfiques

Autors principals:	Helal F. Hetta, Ayman Salama, Turki A. Aljuaid, Yazan T. Mojmami, Riyadh S. Alotibi, Ahmed M. Alqabaly, Nawaf A. Aldosari, Sami A. Alshahri, Walid I. A. Asiri, Raed S. Alamri, Fayez A. Alanazi, Malek S. A. Alenazi, Mohammed H. Albuhayri, Yasmin N. Ramadan, Reem Sayad
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2026-03-01
Col·lecció:	Pharmaceuticals
Matèries:	zanubrutinib BGB-3111 Bruton’s tyrosine kinase inhibitor chronic lymphocytic leukemia Brukinsa small lymphocytic lymphoma
Accés en línia:	https://www.mdpi.com/1424-8247/19/3/467
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!